-
FDA Approves Vadadustat For Treatment of Anemia Due to CKD
29 Mar 2024 16:52 GMT
… least 3 months, the pharmaceutical company announced in a … New England Journal of Medicine.2
Trial Name: Efficacy and … the Correction or Maintenance Treatment of Anemia in Participants … the prevalent trial. The incidences in the darbepoetin alfa group …
-
Akebia’s CKD Anemia Drug Ends Tough Regulatory Path with FDA Approval
28 Mar 2024 15:51 GMT
… will provide “an alternative treatment option for the hundreds of … For Vafseo’s launch, the biotech will work with its U … A New England Journal of Medicine publication in April 2021 showed … drug also had a similar safety and tolerability profile as darbepoetin …
-
Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients
28 Mar 2024 11:19 GMT
… Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment … manufacturing and marketing pharmaceutical products for precision … of patients receiving darbepoetin alfa. Serious … reduction.
Statins: Monitor for statin-related adverse …
-
FDA Approves Vadadustat (Vafseo) Tablets for Anemia Due to CKD in Adult Patients on Dialysis
28 Mar 2024 01:09 GMT
… Food and Drug Administration (FDA) has approved vadadustat (Vafseo) for the treatment of … noninferiority to erythropoiesis-stimulating agent darbepoetin alfa in hemoglobin concentration changes … who participated in our clinical trials that led to this …
-
FDA Approves Vadadustat for Oral Treatment of Anemia Due to Chronic Kidney Disease
28 Mar 2024 18:35 GMT
… FDA has approved vadadustat (Vafseo; Akebia Therapeutics) for the treatment … New England Journal of Medicine.2
The primary safety … study authors.
About The Trials
Trial 1
Trial Name: Efficacy and … DD-CKD trial, while the incidences in darbepoetin alfa were …
-
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
28 Mar 2024 01:37 GMT
… Drug Administration (FDA) has approved Vafseo® (vadadustat) Tablets for the treatment … to seek immediate medical attention if they … ) of patients receiving darbepoetin alfa. Serious worsening … dose reduction.
Statins: Monitor for statin-related adverse …
-
FDA Action Alert: Orchard, ITF, Merck and More
18 Mar 2024 06:20 GMT
… for the treatment of Duchenne muscular dystrophy (DMD). The FDA’s … safety outcomes. Compared with darbepoetin alfa, major adverse cardiovascular … acid is a non-statin oral drug that lowers low-density … risk, according to the biotech, qualified it for the …
-
Erythropoietin Drugs Market Expected To Witness Huge Revenue Growth To 2028
13 Mar 2024 09:31 GMT
… patients.
Anemia Treatment: EPO drugs play a … human erythropoietin) and Darbepoetin Alfa (modified with …
Teva Pharmaceutical Industries Ltd.
Intas Pharmaceuticals
Ranbaxy Laboratories … trials exploring the potential applications of Erythropoietin drugs …
-
Erythropoietin Drugs Market growing significantly at 8.1% CAGR with $330.9 million by 2031
04 Mar 2024 12:50 GMT
… from ESRD treatments and dialysis procedures. EPO drugs have gained … Drugs Market Report Highlights:
By PRODUCTS:
Epoetin-alfa
Epoetin-beta
Darbepoetin … Key Market Players:
INTAS PHARMACEUTICALS, TEVA PHARMACEUTICAL INDUSTRIES LTD., BIOCON, …
-
Drug Trials Snapshots: JESDUVROQ
22 Feb 2024 19:13 GMT
… trials that supported the original FDA approval of this drug … make decisions regarding medical care. Always speak … treatment (epoetin alfa and darbepoetin alfa) for both endpoints.
How were the trials … trial.
PLACEBO: An inactive substance or “sugar pill” …